Skip to main content

Table 1 Detailed dose levels and administration schedules of the study drugs

From: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Study drug

Dose levels

 

K

K-1

K + 1

Arm A: Lenalidomide

20 mg/D 14 days

15 mg/D 21 days

20 mg/D 21 days

Arm B: Ibrutinib*

420 mg (D3 to D14 and D17 to D28)

280 mg (D3 to D14 and D17 to D28)

560 mg (D3 to D14

and D17 to D28)

  1. *Ibrutinib was suspended on the days of methotrexate infusion and the 2 days thereafter. However, if then next methotrexate was delayed for a cause that did not prevent the use of ibrutinib, ibrutinib was continued
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us